AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00915811
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
Trial: NCT00915811
Drug: Busulphan
RxNorm normalized name: Busulphan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
Trial: NCT00915811
Drug: Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
Trial: NCT03229746
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg twice daily orally for at least 12 weeks
Trial: NCT03229746
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mg intravenous weekly for 4 weeks
Trial: NCT00179920
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00179920
Drug: VP-16
RxNorm normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01651130
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
Trial: NCT01780558
Drug: estradiol and progesterone
RxNorm normalized name: ESTRADIOL/PROGESTERONE
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
Trial: NCT00151346
Drug: Bupivacaine and Fentanyl (for traditional epidural)
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
Trial: NCT01260181
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg tablet will be given orally daily.
Trial: NCT03690414
Drug: Atropine sulfate 0.02% eye drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine eye drops
Trial: NCT01796938
Drug: Lacosamide tablet
RxNorm normalized name: Lacosamide Tablets
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose of 100 mg Lacosamide tablet
Trial: NCT05611463
Drug: Camrelizumab Plus Docetaxel and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg) was administered once on day 1 every 3 weeks until disease progression, intolerable toxicity, physician or participant decision or 35 cycles, whichever occurred first. Chemotherapy was received docetaxel (75 mg/m2) and cisplatin (75 mg/m²) on day 2 every 3 weeks for six cycles.
Trial: NCT02831283
Drug: 11C-PBR28
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
Trial: NCT02831283
Drug: 18F-Florbetaben
RxNorm normalized name: florbetaben (18F)
DrugBank: Florbetaben F-18 (DB09148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
Trial: NCT04063683
Drug: Anlotinib Hydrochloride, Paclitaxel, cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle.
Trial: NCT00230490
Drug: pradefovir mesylate
RxNorm normalized name: Pradefovir mesylate
DrugBank: Pradefovir mesylate (DB05478)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230490
Drug: adefovir dipivoxyl
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir (DB13868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02928393
Drug: Basmisanil
RxNorm normalized name: Basmisanil
DrugBank: Basmisanil (DB11877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
Trial: NCT00359814
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
Trial: NCT04594408
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g IV x 1 dose to be administered intraoperatively.
Trial: NCT00659685
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ODT, single-dose, fasting
Trial: NCT00659685
Drug: Zofran ODT
RxNorm normalized name: Zofran ODT
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02369978
Drug: Nifurtimox
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
Trial: NCT02369978
Drug: Benznidazole
RxNorm normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
Trial: NCT03802422
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
Trial: NCT00029315
Drug: Recombinant Tissue Plasminogen Activator (rt-PA)
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01207492
Drug: nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken orally twice daily
Trial: NCT04015141
Drug: Perampanel Oral Suspension
RxNorm normalized name: perampanel Oral Suspension
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel oral suspension.
Trial: NCT04015141
Drug: Perampanel Tablet
RxNorm normalized name: Perampanel Tablets
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel tablet.
Trial: NCT02393599
Drug: Lorcaserin
RxNorm normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg 2 times per day from Day 3 to 9 and one time on Day 10
Trial: NCT02393599
Drug: Cocaine Infusion
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
Trial: NCT03013751
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug
Trial: NCT01048229
Drug: Rasagiline
RxNorm normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg rasagiline once daily (plus placebo twice daily)
Trial: NCT01048229
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
Trial: NCT04618497
Drug: Methoxyflurane
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient in the methoxyflurane group will use one Penthrox inhaler under supervision of trained personnel. After priming the inhaler with 3 mL of methoxyflurane, patient is instructed to inhale through the mouthpiece to obtain analgesia, and then exhale back into the mouthpiece so that any unmetabolized methoxyflurane can be adsorbed by activated charcoal chamber. First few breaths should be gentle and then breathe normally through Inhaler. Onset of pain relief is rapid and occurs after 6-10 inhalations. If stronger analgesia is required, patient can cover the diluter hole with a finger during inhalation. Patients are able to titrate the amount of methoxyflurane inhaled and should be instructed to inhale intermittently to achieve adequate pain control.
Trial: NCT02625870
Drug: Omega-3-Acid Ethyl Esters 90 Soft Capsules
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
Trial: NCT03121352
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 4.5 IV day 1 of 21-day cycle
Trial: NCT03121352
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75mg/m2 IV days 1, 8 and 15 of 21-day cycle
Trial: NCT03121352
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg IV every 21 days
Trial: NCT00115427
Drug: Liatermin (r-metHuGDNF)
RxNorm normalized name: pantolactone, (R)-
DrugBank: Liatermin (DB06489)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03865407
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
Trial: NCT03336398
Drug: Ketamine Hydrochloride in saline
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
Trial: NCT03336398
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline will be administered with the other MRS scan
Trial: NCT04445467
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir
Trial: NCT02126644
Drug: 70% glycolic acid
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04045613
Drug: Derazantinib 300 mg once daily monotherapy
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib was administered orally at a dose of 300 mg once daily
Trial: NCT04045613
Drug: Derazantinib 200 mg once daily + atezolizumab 1200 mg
RxNorm normalized name: eslicarbazepine
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Trial: NCT04045613
Drug: Derazantinib 300 mg once daily+ atezolizumab 1200 mg
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Trial: NCT04045613
Drug: Derazantinib 200 mg twice daily + atezolizumab 1200 mg
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks
Trial: NCT04045613
Drug: Derazantinib 300 mg once daily monotherapy (QD)
DrugBank: Derazantinib (DB14889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derazantinib was administered orally at a dose of 300 mg once daily
Trial: NCT04045613
Drug: Derazantinib 300 mg once daily + atezolizumab 1200 mg
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks
Trial: NCT04045613
Drug: Derazantinib 200 mg twice daily monotherapy
RxNorm normalized name: clindamycin
DrugBank: Derazantinib (DB14889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Derazantinib was administered orally at a dose of 200 mg twice daily
Trial: NCT00999128
Drug: GDC-0941
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00999128
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT04561817
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg PO daily: day 1-21 of 28 day cycle
Trial: NCT04561817
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 IV weekly: day 1, 8, 15 of 28 day cycle
Trial: NCT02844582
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02844582
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02625870
Drug: Corn Oil
RxNorm normalized name: Corn Oil
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
Trial: NCT00687102
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tamoxifen plus placebo daily for 5 years
Trial: NCT05169450
Drug: Diterpene ginkgolides meglumine injection
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.
Trial: NCT03826992
Drug: Vyxeos
RxNorm normalized name: Vyxeos
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on Days 1, 3, and 5.
Trial: NCT03826992
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax Dose:~1. Dose Level 0 - weight based daily dosing for 21 days~2. Dose Level -1 - weight based daily dosing for 14 days~3. Dose Level -2- weight based daily dosing for 10 days~4. Dose Level -3- weight based daily dosing for 7 days
Trial: NCT02797041
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
Trial: NCT04202003
Drug: TJ011133
RxNorm normalized name: Immunoglobulin g4(228-proline), anti-(human cd47 antigen) (human monoclonal tj011133 .gamma.4-chain), disulfide with human monoclonal tj011133 .kappa.-chain, dimer
DrugBank: Lemzoparlimab (DB17572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an open-label Phase 1/2a clinical study. The study will be conducted in two parts: Part I: Phase 1 dose escalation, TJ011133 is tentatively scheduled to be administered once weekly in 28-day treatment cycles;Part II: Phase 2a study TJ011133 will be administered at a dose of 30 mg/kg once weekly, and AZA will be administered at a dose of 75 mg/m2 by subcutaneous injection for 7 consecutive days from D1 to D7 in 28-day treatment cycles.
Trial: NCT00687102
Drug: raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral raloxifene plus placebo daily for 5 years
Trial: NCT02224846
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00818038
Drug: BG0002 (natalizumab)
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
Trial: NCT02119104
Drug: Prevenar (13v)
RxNorm normalized name: Prevnar 20
DrugBank: Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevenar (13v)
Trial: NCT00756977
Drug: polyethylene glycol 3350 based bowel preparation
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multi-dose preparation for oral administration prior to colonoscopy
Trial: NCT02606877
Drug: nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02606877
Drug: pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03005782
Drug: REGN3767
RxNorm normalized name: Anti-lag-3 monoclonal antibody regn3767
DrugBank: Fianlimab (DB18858)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03005782
Drug: cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03863392
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction of labor
Trial: NCT01558089
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: according to SmPC and clinical practice
Trial: NCT00934531
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline.
Trial: NCT00855530
Drug: amibegron (SR58611A)
RxNorm normalized name: Vibegron
DrugBank: Amibegron (DB05395)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral administration of 300 mg twice daily
Trial: NCT01903434
Drug: Evacetrapib
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01797432
Drug: Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
Trial: NCT01884285
Drug: Part C1: Abiraterone acetate combination with AZD8186
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
Trial: NCT01884285
Drug: Part D2 AZD2014 combination with AZD8186
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
Trial: NCT01884285
Drug: Part C2: Abiraterone acetate combination with AZD8186
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
Trial: NCT02046915
Drug: Imnovid (pomalidomide)
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02046915
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02046915
Drug: Endoxan (Cyclophosphamide)
RxNorm normalized name: aspirin / oxycodone hydrochloride / oxycodone terephthalate Oral Tablet [Endodan]
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes